Oral Anti-TNFα Antibody
Inflammatory/Autoimmune Diseases (e.g., Rheumatoid Arthritis, IBD)
Key Facts
About Intract Pharma
Intract Pharma is a private, preclinical-stage biotech specializing in oral drug delivery platforms for biologics. Founded in 2006 as a spin-out from University College London (UCL), the company leverages over two decades of research to develop technologies that target drug release to specific regions of the GI tract, aiming to replace injectable therapies with oral tablets or capsules. Its lead program is an oral anti-TNFα antibody, and the company is pursuing strategic moves, including a planned merger with Tharimmune, to advance its pipeline. Intract operates as a platform company, likely seeking licensing deals and partnerships to develop oral formulations of biologic drugs.
View full company profile